PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

计划入组 105 人 · 首次发布于 2019 年 5 月 31 日

PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System

计划入组 32 人 · 首次发布于 2017 年 4 月 24 日

Percutaneous Deep Vein Arterialization Post-Market Study

计划入组 28 人 · 首次发布于 2019 年 1 月 17 日

C213 Microneedle System

drug delivery system

endocannabinoid system activator

Limflow Inc.

United States

Ryder System

United States

GOSHEN HEALTH SYSTEM

United States

Amavita Heart and Vascular Partners with LimFlow for CLTI Treatment

VIVA24: Late-Breaking Trials Highlight Advances in Peripheral Artery Disease Treatment

VIVA24: Late-Breaking Trials Highlight Advances in Vascular Intervention